Mass Tort brief
Settlement Deadlines and Device Docket Splits
Pfizer nears a master resolution in Depo-Provera while the judicial panel fragments spinal stimulator suits and consolidates Apple AirTag claims.
Mass Tort
Pfizer is moving to resolve the bulk of Depo-Provera brain tumor claims before facing a federal jury — averting catastrophic trial exposure by locking plaintiffs into structured payout matrixes.
BackgroundDepo-Provera is an injectable birth control drug containing medroxyprogesterone acetate that has been prescribed to millions of women globally since the 1990s. Thousands of women developed intracranial and spinal meningioma tumors, alleging Pfizer failed to warn about elevated tumor risks.
- Judge M. Casey Rodgers convened a critical status conference to finalize the Master Settlement Agreement registry, forcing both sides to resolve claimant qualification criteria before the Thanksgiving deadline.
- The court appointed special masters to structure the Supplemental Compensation Fund, establishing strict evidentiary guidelines to screen out unverified injury filings before fund allocation.
- Initial financial disbursements to eligible meningioma claimants are scheduled to begin in early 2027, setting up the first major payouts in the nationwide litigation.
Mass Tort
By clearing initial scientific hearings, 4,000 GLP-1 stomach paralysis claims advance toward bellwether trials — stripping Novo Nordisk and Eli Lilly of early preemption defenses.
BackgroundGLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro have become blockbuster treatments for diabetes and chronic weight management. Thousands of patients allege the drugs cause irreversible gastroparesis, intestinal blockages, and non-arteritic anterior ischemic optic neuropathy blindness.
- Judge Marston is evaluating over 4,000 active stomach paralysis claims in MDL 3094 alongside 247 companion blindness lawsuits in MDL 3163, assessing common general causation testimony.
- The court is weighing whether plaintiffs must provide objective gastric emptying scintigraphy scans or can rely on documented clinical symptoms, which could disqualify hundreds of claimants.
- Monthly pre-trial conferences through late 2026 will select the initial bellwether cases, moving the pharmaceutical giants toward their first federal jury trials.
Mass Tort
By rejecting an industry-wide mega-MDL, the judicial panel forces Abbott and Nevro to defend device design and recall histories on separate trial tracks — preventing manufacturers from sharing legal defense costs.
BackgroundSpinal cord stimulators are surgically implanted pulse generators that transmit electrical currents into the spine to manage chronic pain. Recent FDA Class I recalls cited severe electrical shocks, lead migration, and software lockouts that left patients unable to turn off defective generators.
- Judge Lindsay C. Jenkins will preside over Abbott claims in Illinois, focusing discovery on recalled Proclaim and Infinity neurostimulator implants linked to battery failures.
- Nevro claims regarding electrical shock injuries and unapproved modifications on Senza systems were transferred to Northern California, exposing the smaller device maker to standalone trial risks.
- The twin proceedings join an existing Boston Scientific stimulator proceeding, consolidating neuromodulation litigation across three federal judges and splitting plaintiff steering resources.
Mass Tort
Centralizing AirTag stalking claims into a federal MDL forces Apple to defend the physical safety architecture of its consumer devices in court — putting its product design on trial.
BackgroundApple released AirTags in 2021 as coin-sized Bluetooth devices designed to track personal belongings through the company's Find My network. Stalking victims and domestic violence advocates allege Apple released a dangerous product with inadequate safety alerts, facilitating harassment and violence.
- The panel created MDL No. 3199 in San Francisco, rejecting Apple's arguments that individualized stalking incidents barred coordinated pre-trial discovery proceedings.
- Plaintiffs allege defective product design and negligence, asserting Apple failed to deploy real-time safeguards against stalking on both Android and iOS devices.
- Apple resolved 20 individual stalking lawsuits before the hearing, but hundreds of refiled tort actions remain pending across 19 federal districts.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
